Sepracor, Inc. Release: Newly Published Data Show Efficacy And Safety Of LUNESTA(R) In Elderly Patients With Insomnia
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced the publication of results of a large, randomized, double-blind, placebo-controlled, two-week study of LUNESTA® brand of eszopiclone for the treatment of insomnia in elderly patients. The study was conducted in 49 centers across the U.S. and included elderly patients (64-86 years of age; n=264) who met DSM-IV® 1 criteria for primary insomnia and screening polysomnographic (PSG; a type of study conducted in a sleep laboratory) criteria. Patients were randomized to two weeks of nightly treatment with either LUNESTA 2 mg or placebo. Efficacy and safety were assessed at overnight sleep laboratory visits using PSG measures and Interactive Voice Response System (IVRS) morning and evening questionnaires, and through patient-reported IVRS morning and evening questionnaires at home. The results were published in the September 2006 edition of the journal, Current Medical Research and Opinion.